Patent ID: 11965023
Assignee: ALECTOR LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 1:
2. The method of claim 1, wherein the disease, disorder, or injury is cancer, and wherein the anti-Siglec-5 antibody inhibits one or more Siglec-5 activities selected from the group consisting of:
(a) promoting proliferation, maturation, migration, differentiation, and/or functionality of one or more of immunosuppressor dendritic cells, immunosuppressor macrophages, immunosuppressor neutrophils, immunosuppressor NK cells, myeloid derived suppressor cells, tumor-associated macrophages, tumor-associated suppressor neutrophils, tumor-associated suppressor NK cells, and regulatory T cells;
(b) enhancing infiltration of one or more of immunosuppressor dendritic cells, immunosuppressor macrophages, immunosuppressor neutrophils, immunosuppressor NK cells, myeloid derived suppressor cells, tumor-associated macrophages, tumor-associated suppressor neutrophils, tumor-associated suppressor NK cells, and regulatory T cells into tumors;
(c) increasing number of tumor-promoting myeloid/granulocytic immune-suppressive cells in a tumor, in peripheral blood, or other lymphoid organ;
(d) enhancing tumor-promoting activity of myeloid-derived suppressor cells (MDSC);
(e) increasing expression of tumor-promoting cytokines in a tumor or in peripheral blood, optionally wherein the tumor-promoting cytokines are TGF-beta or IL-10;
(f) increasing tumor infiltration of tumor-promoting FoxP3+ regulatory T lymphocytes;
(g) decreasing activation of tumor-specific T lymphocytes with tumor killing potential;
(h) decreasing infiltration of tumor-specific T lymphocytes with tumor killing potential;
(i) decreasing infiltration of tumor-specific NK cells with tumor killing potential;
(j) decreasing the tumor killing potential of NK cells;
(k) decreasing infiltration of tumor-specific B lymphocytes with potential to enhance immune response;
(l) increasing tumor volume;
(m) increasing tumor growth rate;
(n) increasing metastasis;
(o) increasing rate of tumor recurrence;
(p) decreasing efficacy of one or more immune-therapies that modulate anti-tumor T cell responses, optionally wherein the one or more immune-therapies are immune-therapies that target one or more target proteins selected from the group consisting of PD1/PDL1, CD40, OX40, ICOS, CD28, CD137/4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD30, TIGIT, VISTA, KIR, GALS, TIM1, TIM3, TIM4, A2AR, LAG3, DR-5, CD2, CD5, CD39, CD73, DR-5, and any combination thereof, or one or more cancer vaccines;
(q) inhibition of PLCγ/PKC/calcium mobilization; and
(r) inhibition of PI3K/Akt, Ras/MAPK signaling.